Articolul precedent |
Articolul urmator |
![]() |
![]() ![]() |
Ultima descărcare din IBN: 2024-01-17 10:08 |
![]() BACALIM, Lilia, GHIDIRIM, Nicolae, BARBA, Loridana, RUSSU, Olesea, MUNTEANU, Andrei, RUSU, Mihail. The level of correspondence the diagnosis in the precancerous conditions of the mammary gland. In: Perspectives of the Balkan medicine in the post COVID-19 era: The 37th Balkan Medical Week. The 8th congress on urology, dialysis and kidney transplant from the Republic of Moldova “New Horizons in Urology”, Ed. 37, 7-9 iunie 2023, Chişinău. București: Balkan Medical Union, 2023, Ediția 37, p. 194. ISSN Print: ISSN 1584-9244 ISSN-L 1584-9244 Online: ISSN 2558-815X. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Perspectives of the Balkan medicine in the post COVID-19 era Ediția 37, 2023 |
||||||
Congresul "Perspectives of the Balkan medicine in the post COVID-19 era" 37, Chişinău, Moldova, 7-9 iunie 2023 | ||||||
|
||||||
Pag. 194-194 | ||||||
|
||||||
![]() |
||||||
Rezumat | ||||||
Introduction. Precancerous conditions of the mammary gland are a series of changes that occur in the mammary glands and, if not treated, can turn into cancer. About one in two women shows symptoms of the presence of a formation in the breasts. cancer compared with atypical hyperplasia, which is consistent with a significantly increased risk. Matherial and methods. A retrospective hospital-based study was conducted in the Oncology Institute, Department of Mammology, Chisinau, Republic of Moldova. In the study were included 374 patients, from 2021 – 178 patients and from 2022 – 196 patients. There were 354 female patients, which constitutes 94.65%, in the remaining 20 cases – male (5.34%). Results. In our research, patients with the following precancerous conditions were included: localized fibrocystic mastopathy (n=221; 59.09%), intraductal papilloma (n=84; 22.45%), gynecomastia (n=20; 5.34%) and lipogranuloma (n=49;13.1%). For detection, the following investigation methods were performed: palpation of the mammary gland - 374 cases (100%), USG - 344 cases (92%), mammography - 148 cases (39.57%), cytology through fine-needle aspiration - 290 cases (77.54%) and by smear-on the slide – 84 cases (22.45%). The level of correspondence of the primary diagnosis with the definitive clinical diagnosis in the case of fibrocystic mastopathy was 60% (n=133 out of 221), intraductal papilloma 83% (n=69 out of 84), lipogranuloma - 95% (n=47 out of 49) and gynecomastia – 90% (n=18 of 20). Conclusion. In over 60% of cases, the primary diagnosis corresponds to the definitive clinical diagnosis, in the rest of the cases, benign tumors or even cancer are detected. |
||||||
|
Cerif XML Export
<?xml version='1.0' encoding='utf-8'?> <CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'> <cfResPubl> <cfResPublId>ibn-ResPubl-193329</cfResPublId> <cfResPublDate>2023</cfResPublDate> <cfVol>Ediția 37</cfVol> <cfStartPage>194</cfStartPage> <cfISBN></cfISBN> <cfURI>https://ibn.idsi.md/ro/vizualizare_articol/193329</cfURI> <cfTitle cfLangCode='EN' cfTrans='o'>The level of correspondence the diagnosis in the precancerous conditions of the mammary gland</cfTitle> <cfAbstr cfLangCode='EN' cfTrans='o'><p>Introduction. Precancerous conditions of the mammary gland are a series of changes that occur in the mammary glands and, if not treated, can turn into cancer. About one in two women shows symptoms of the presence of a formation in the breasts. cancer compared with atypical hyperplasia, which is consistent with a significantly increased risk. Matherial and methods. A retrospective hospital-based study was conducted in the Oncology Institute, Department of Mammology, Chisinau, Republic of Moldova. In the study were included 374 patients, from 2021 – 178 patients and from 2022 – 196 patients. There were 354 female patients, which constitutes 94.65%, in the remaining 20 cases – male (5.34%). Results. In our research, patients with the following precancerous conditions were included: localized fibrocystic mastopathy (n=221; 59.09%), intraductal papilloma (n=84; 22.45%), gynecomastia (n=20; 5.34%) and lipogranuloma (n=49;13.1%). For detection, the following investigation methods were performed: palpation of the mammary gland - 374 cases (100%), USG - 344 cases (92%), mammography - 148 cases (39.57%), cytology through fine-needle aspiration - 290 cases (77.54%) and by smear-on the slide – 84 cases (22.45%). The level of correspondence of the primary diagnosis with the definitive clinical diagnosis in the case of fibrocystic mastopathy was 60% (n=133 out of 221), intraductal papilloma 83% (n=69 out of 84), lipogranuloma - 95% (n=47 out of 49) and gynecomastia – 90% (n=18 of 20). Conclusion. In over 60% of cases, the primary diagnosis corresponds to the definitive clinical diagnosis, in the rest of the cases, benign tumors or even cancer are detected.</p></cfAbstr> <cfResPubl_Class> <cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId> <cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId> <cfStartDate>2023T24:00:00</cfStartDate> </cfResPubl_Class> <cfResPubl_Class> <cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId> <cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId> <cfStartDate>2023T24:00:00</cfStartDate> </cfResPubl_Class> <cfPers_ResPubl> <cfPersId>ibn-person-43134</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2023T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-11719</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2023T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-88840</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2023T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-94719</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2023T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-18986</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2023T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-25203</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2023T24:00:00</cfStartDate> </cfPers_ResPubl> </cfResPubl> <cfPers> <cfPersId>ibn-Pers-43134</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-43134-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2023T24:00:00</cfStartDate> <cfFamilyNames>Бакалым</cfFamilyNames> <cfFirstNames>Лилия</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-11719</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-11719-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2023T24:00:00</cfStartDate> <cfFamilyNames>Гидирим</cfFamilyNames> <cfFirstNames>Николае</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-88840</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-88840-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2023T24:00:00</cfStartDate> <cfFamilyNames>Barba</cfFamilyNames> <cfFirstNames>Loridana</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-94719</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-94719-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2023T24:00:00</cfStartDate> <cfFamilyNames>Russu</cfFamilyNames> <cfFirstNames>Olesea</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-18986</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-18986-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2023T24:00:00</cfStartDate> <cfFamilyNames>Munteanu</cfFamilyNames> <cfFirstNames>Andrei</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-25203</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-25203-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2023T24:00:00</cfStartDate> <cfFamilyNames>Rusu</cfFamilyNames> <cfFirstNames>Mihail</cfFirstNames> </cfPersName_Pers> </cfPers> </CERIF>